
The FDA granted fast track designation to elticertinib for pretreated EGFR exon 20 insertion–mutated NSCLC.
Samuel Rosner, MD, and Laura Alder, MD, discuss treatment approaches following frontline use of the MARIPOSA or FLAURA-2 regimens in EGFR-mutated NSCLC.
Samuel Rosner, MD, and Laura Alder, MD, explore treatment sequencing considerations following frontline use of combination regimens in EGFR-mutated non–small cell lung cancer. Alder discusses how evolving resistance patterns may influence subsequent therapy selection after combination-based strategies. Rosner highlights current uncertainties in sequencing after these regimens and underscores the need for additional clinical data to guide treatment decisions.






